News

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...
Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...
The breakup comes due to Novo Nordisk’s claims that Hims & Hers has ‘failed to adhere to the law’ by continuing to sell compounded versions of Wegovy. This morning, the Danish pharmaceutical giant ...
Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss drug.
Hims & Hers stands out for personalized, compounded medications and consistent margin expansion but faces rising risks tied ...
Hims & Hers Health (HIMS -3.91%) is a telehealth company that offers personalized solutions for its customers. And demand has ...
Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.